Simplifying IgG therapy with flexIG

As healthcare around the world goes increasingly digital, mobile health apps are elevating patient care through real-time treatment monitoring and personalised support. With more patients and health care providers adopting these tools, mobile health apps are transforming how individuals stay engaged with their health, adhere to treatment plans, and communicate with their care teams. In fact, in 2024, 43% of the U.S. population used health apps, reflecting the growing trend of digital health adoption across the globe.1

One such innovative app is flexIG – Octapharma’s digital therapy diary – which empowers patients to actively manage their subcutaneous human normal immunoglobulin (SCIg) treatments.  “flexIG is a significant milestone providing patients with an easily accessible cutting-edge tool to oversee and track their therapy,” says Anne-Lise Roger, Global Brand Manager, Immunotherapy Business Unit. “Ultimately, flexIG can also strengthen adherence and enhance communication with healthcare providers.”

"Offering a transformative way for patients to take control of their own treatment, flexIG is a major advancement in patient care. Giving patients the ability to monitor their treatment digitally, receive reminders and share reports with the healthcare team strengthens the patient-physician relationship, reducing the likelihood of missed treatments and ensuring therapy is followed as prescribed,” says Dr. Raffaela Neri, Clinical Immunologist, Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy. “Additionally, thanks to the detailed reports my patients are able to share with me, I gain valuable insights into their IG routine, allowing me to optimise their therapy for improved outcomes. flexIG is not just an app for therapy monitoring, but an ally for improving treatment effectiveness and ensuring safer and more targeted healthcare. I highly recommend it to anyone managing patients undergoing subcutaneous immunoglobulin therapy."

“The new flexIG app from Octapharma makes immunoglobulin-therapy easier,” adds Sandra Knoche, Managing Director at HWMT Medizinprodukte GmbH, Germany, a healthcare provider specialising in managing subcutaneous immunoglobulin therapy by coordinating prescriptions, ensuring timely medication delivery, and providing patient training.

The flexIG app has a number of key features available to users:

•  Helpful reminders: Easily schedule injections, set doses, and receive timely reminders for treatments.

• Tracks injections: Record medication details, injection sites, and times, along with any personal notes.

• Appointment management: Create, store, and receive reminders for upcoming therapy-related appointments.

• Access information anytime: Keep a secure, easy-to-access record of injections on a smartphone.

• Share reports with healthcare professionals: Generate and share a PDF report of  treatment history with the user’s healthcare team.

The flexIG app was launched in Germany and Italy in October 2024, with many other countries – including those outside of the EU – set to follow suit.

^{1. Statista. Accessed February 5, 2024. http://www.statista.com/forecasts}